We are expanding the curative potential of bone marrow transplant to more patients who can benefit. We are advancing a broad portfolio of products in development, including our most advanced program, MGTA-456, which is currently being studied in Phase 1/2 clinical trials.

Today bone marrow transplants are complicated, toxic and high-risk. We are working to change that for patients with autoimmune diseases, blood cancers, and rare genetic diseases.